<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02063776</url>
  </required_header>
  <id_info>
    <org_study_id>13NU02</org_study_id>
    <nct_id>NCT02063776</nct_id>
  </id_info>
  <brief_title>Haemodiafiltration vs Conventional Haemodialysis in Children</brief_title>
  <acronym>3H</acronym>
  <official_title>The Effects of Haemodiafiltration (HDF) vs Conventional Haemodialysis (HD) on Growth and Cardiovascular Markers in Children - 3H (HDF, Hearts and Height) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Great Ormond Street Hospital for Children NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Great Ormond Street Hospital for Children NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Children on conventional haemodialysis (HD) die of heart disease. Also, they can be&#xD;
      malnourished and short. Haemodiafiltration (HDF) is a newer type of dialysis that achieves&#xD;
      better removal of toxins and excess fluid than HD. On HDF, adults have a longer survival and&#xD;
      children show improved growth, but mechanisms are not understood.&#xD;
&#xD;
      We will follow children in the UK and Europe to compare HDF and HD. We will monitor growth,&#xD;
      heart and blood vessel scans, blood markers and quality of life. If the 3H&#xD;
      (HDF-Hearts-Height) study shows reduced cardiovascular morbidity and better growth, HDF may&#xD;
      be adopted as the preferred type of dialysis in children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Children on conventional haemodialysis (HD) have a 1000-fold higher mortality&#xD;
      than their healthy peers and can have malnutrition and growth retardation. Haemodiafiltration&#xD;
      (HDF) achieves better clearance of uraemic solutes across a wide molecular-weight range and&#xD;
      performs greater ultrafiltration than conventional HD. Randomised controlled trials in adults&#xD;
      have shown 35-45% improved survival and reduced cardiovascular mortality on HDF with high&#xD;
      convection volumes. Excellent catch-up growth has been demonstrated in children on HDF, but&#xD;
      mechanisms are poorly understood.&#xD;
&#xD;
      Hypothesis: HDF improves the cardiovascular risk profile, growth and quality of life (QoL)&#xD;
      compared to conventional HD. Primary outcome measures are carotid intima-media thickness&#xD;
      (cIMT) and height standard deviation score (SDS).&#xD;
&#xD;
      Plan of investigation: Incident and prevalent patients on HDF or HD who are expected to&#xD;
      remain on dialysis for &gt;6-months and who have a single pool Kt/v&gt;1.2 will be compared in a&#xD;
      1:1 study design. Anthropometric measures (height SDS, body mass index SDS) and QoL&#xD;
      questionnaires will be monitored at baseline and 6-monthly. Cardiovascular measures (cIMT,&#xD;
      pulse wave velocity, left ventricular mass index and 24-hour BP) will be measured annually.&#xD;
      6-monthly blood tests will measure nutritional biomarkers, mineral dysregulation,&#xD;
      inflammation and middle-molecule clearance. Outcome measures will be standardised to the&#xD;
      convective clearance dose per m2 body surface area. Recruitment will continue for 2Â½ years&#xD;
      with minimum follow-up of 6-months.&#xD;
&#xD;
      Children will be recruited from all UK dialysis units, but small patient numbers (10-12/year)&#xD;
      necessitate collaborations with European centres. HDF and HD patients across Europe who are&#xD;
      part of the Cardiovascular Comorbidity in Childhood CKD (4C) study will be included and&#xD;
      vascular scans will be captured from this study. From ESPN/ERA-EDTA registry data we estimate&#xD;
      ~100 children on HDF over the study period.&#xD;
&#xD;
      Outcomes: If the 3H (HDF-Hearts-Height) study shows that HDF reduces cardiovascular morbidity&#xD;
      and improves growth it may lead to HDF being adopted as the standard for in-centre dialysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>1. Change in carotid artery intima-media thickness (cIMT) standard deviation score (SDS)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in height SDS</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>For nutritional status 1. Body mass index SDS 2. Markers of appetite regulation and nutritional status</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For cardiovascular status 1. 24-hour mean arterial BP SDS 2. Left ventricular mass index 3. Pulse wave velocity SDS 4. Biomarkers of cardiovascular disease</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL) questionnaires</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">150</enrollment>
  <condition>Children</condition>
  <condition>Haemodialysis</condition>
  <condition>Haemodiafiltration</condition>
  <arm_group>
    <arm_group_label>Children on HDF</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Children on conventional HD</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum only&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        -  HDF patients will be compared with age-matched HD patients in a 1:1 study design.&#xD;
&#xD;
          -  Children will be recruited from paediatric dialysis units within the UK and also&#xD;
             centres in Europe, through the 4C-study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. All children 5 - 21 years age undergoing HDF in paediatric dialysis centres (incident&#xD;
             and prevalent patients)&#xD;
&#xD;
          2. Age-matched HD patients&#xD;
&#xD;
          3. Prevalent HDF and HD patients must achieve a single pool Kt/v&gt;1.2 in the month&#xD;
             preceding recruitment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Children in whom a living donor kidney transplant is planned within 6-months of start of&#xD;
        dialysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rukshana C Shroff, MD FRCPCH PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Great Ormond Street Hospital for Children NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rukshana Shroff</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>February 13, 2014</study_first_submitted>
  <study_first_submitted_qc>February 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2014</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haemodiafiltration (HDF)</keyword>
  <keyword>Haemodialysis (HD)</keyword>
  <keyword>Children</keyword>
  <keyword>Carotid intima media thickness</keyword>
  <keyword>Pulse wave velocity</keyword>
  <keyword>Height standard deviation score</keyword>
  <pending_results>
    <submitted>September 9, 2019</submitted>
    <returned>October 1, 2019</returned>
    <submitted>April 23, 2020</submitted>
    <returned>May 6, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

